Trial Profile
A Phase I, Open-Label, Non-Randomized, Dose Escalation, Multi Center Study to Assess the Safety and Cardiovascular Effects of Autologous Skeletal Myoblast Implantation by a Transendocardial Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s) With Previous Placement of ICD
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Muscle-derived autologous stem cell therapy Bioheart (Primary)
- Indications Coronary artery disease; Heart failure; Myocardial infarction
- Focus Therapeutic Use
- Sponsors U.S. Stem Cell
- 11 Dec 2014 New trial record